View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsAceragen 将来の成長Future 基準チェック /06現在、 Aceragenの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率85.20%EPS成長率Biotechs 収益成長25.3%収益成長率-161.8%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日01 Mar 2023今後の成長に関する最新情報Price Target Changed • Aug 15Price target decreased by 88% to US$17.00Down from US$142, the current price target is provided by 1 analyst. New target price is 3,909% above last closing price of US$0.42. Stock is down 94% over the past year. The company is forecast to post a net loss per share of US$2.18 next year compared to a net loss per share of US$7.18 last year.Price Target Changed • Mar 16Price target increased to US$8.60Up from US$7.83, the current price target is an average from 4 analysts. New target price is 84% above last closing price of US$4.68. Stock is up 337% over the past year.分析記事 • Jan 31When Will Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Become Profitable?With the business potentially at an important milestone, we thought we'd take a closer look at Idera Pharmaceuticals...すべての更新を表示Recent updatesPrice Target Changed • Aug 15Price target decreased by 88% to US$17.00Down from US$142, the current price target is provided by 1 analyst. New target price is 3,909% above last closing price of US$0.42. Stock is down 94% over the past year. The company is forecast to post a net loss per share of US$2.18 next year compared to a net loss per share of US$7.18 last year.お知らせ • May 31Aceragen Receives Nasdaq Notice Regarding Delayed Form 10-Q FilingAceragen, Inc. announced that on May 24, 2023, the Company received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company had not yet filed its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023 (the “Form 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic financial reports with the Securities and Exchange Commission. The Nasdaq notice has no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Global Market. The Company has until July 24, 2023 to submit to Nasdaq a plan to regain compliance. If Nasdaq accepts the Company’s plan, then Nasdaq may grant the Company up to 180 calendar days from the Form 10-Q’s original due date, or November 20, 2023, to regain compliance. If the Company is unable to make such filings by July 24, 2023, the Company intends to submit to Nasdaq a plan to regain compliance.お知らせ • May 16Aceragen, Inc. announced delayed 10-Q filingOn 05/15/2023, Aceragen, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 06Aceragen, Inc. Announces John Kirby No Longer Serves as Chief Financial OfficerAceragen, Inc. announced that effective as of the Effective Date, John Kirby no longer serves as the Company’s Chief Financial Officer or is employed by the Company. Mr. Kirby is entitled to certain payments and post-termination benefits as set forth in his employment continuation and retention bonus letter agreement and his Severance and Change of Control Agreement with the Company, each as described on pages 80, 88 and 89 of the 2022 Form 10-K.お知らせ • Feb 07Aceragen, Inc. Announces Recommendation of Data Monitoring Committee in Terra StudyAceragen, Inc. announced the recommendation of its independent Data Monitoring Committee (DMC) in regard to the on-going TERRA Phase 2 study of ACG-701 in patients with melioidosis. The DMC is responsible for providing oversight of safety and efficacy for this study and has recommended the TERRA study continue without modification. The DMC review was a planned meeting held in order to monitor the safety of the seriously ill subjects participating in the TERRA study. Aceragen has executed an ~$50 million development partnership with the Department of Defense’s Defense Threat Reduction Agency (“DTRA”) to investigate ACG-701 as a potential medical countermeasure for melioidosis, a life-threatening infection caused by the B. pseudomallei pathogen. This program is centered around a Phase 2 trial, the TERRA study (NCT05105035), which is a randomized double-blind, placebo-controlled trial conducted in hospitalized melioidosis patients. TERRA was initiated in May 2022 and continues to actively enroll patients with a data read-out expected in the fourth quarter of 2023.お知らせ • Feb 04Aceragen, Inc. Announces Bryant D. Lim to Leave as Senior Vice President, Chief Business Officer and General Counsel of the Company, Effective February 17, 2023Aceragen, Inc. announced that on February 3, 2023, Bryant D. Lim will be leaving his role as Senior Vice President, Chief Business Officer and General Counsel of the Company, effective February 17, 2023, to pursue another opportunity.Seeking Alpha • Sep 28Idera Pharmaceuticals completes acquisition of AceragenIdera Pharmaceuticals (NASDAQ:IDRA) has completed the acquisition of privately-held biotechnology company Aceragen in a stock-for-stock transaction. The acquisition, not subject to the approval of Idera stockholders, was unanimously approved by the board of both the companies. The combined cash of the two companies is expected help in funding the advancement of Aceragen's pipeline through 2023. Idera's former CEO, Vincent Milano, has been named board chair. Aceragen's former CEO, John Taylor, succeeds Milano. Additionally, Aceragen's former chief medical officer, Carl Kraus, will serve in that role for Idera. Also, Aceragen's former COO, Daniel Salain, will serve in that role for Idera. And, Andy Jordan, Aceragen's former CFO has been appointed chief strategy officer for Idera. IDRA shares were trading +19.85% post-market. Source: Press Release分析記事 • Aug 24We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn RateJust because a business does not make any money, does not mean that the stock will go down. For example, although...Board Change • Jun 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 2 highly experienced directors. Independent Chairman Mike Dougherty was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.分析記事 • May 11We Think Idera Pharmaceuticals (NASDAQ:IDRA) Needs To Drive Business Growth CarefullyJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Board Change • May 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 2 highly experienced directors. Independent Chairman Mike Dougherty was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Director Overboarding • Aug 03Director Vincent Milano has joined 3rd company boardPresident, CEO & Director Vincent Milano has been appointed to the board of BioCryst Pharmaceuticals, Inc. (NasdaqGS:BCRX). Milano now sits on a total of 3 company boards. With 3 board positions including the role of CEO at Idera Pharmaceuticals, Inc. (NasdaqCM:IDRA), the director is at risk of having too many board obligations according to the Simply Wall St Risk Model.Director Overboarding • Aug 03Director Vincent Milano has joined 3rd company boardPresident, CEO & Director Vincent Milano has been appointed to the board of BioCryst Pharmaceuticals, Inc. (NasdaqGS:BCRX). Milano now sits on a total of 3 company boards. With 3 board positions including the role of CEO at Idera Pharmaceuticals, Inc. (NasdaqCM:IDRA), the director is at risk of having too many board obligations according to the Simply Wall St Risk Model.Director Overboarding • Aug 03Director Vincent Milano has joined 3rd company boardPresident, CEO & Director Vincent Milano has been appointed to the board of BioCryst Pharmaceuticals, Inc. (NasdaqGS:BCRX). Milano now sits on a total of 3 company boards. With 3 board positions including the role of CEO at Idera Pharmaceuticals, Inc. (NasdaqCM:IDRA), the director is at risk of having too many board obligations according to the Simply Wall St Risk Model.Recent Insider Transactions • Jun 22Senior VP & COO recently bought US$60k worth of stockOn the 18th of June, Daniel Soland bought around 50k shares on-market at roughly US$1.19 per share. In the last 3 months, there was an even bigger purchase from another insider worth US$101k. Daniel has been a buyer over the last 12 months, purchasing a net total of US$98k worth in shares.Recent Insider Transactions • Jun 04Independent Chairman recently bought US$101k worth of stockOn the 1st of June, Michael Dougherty bought around 85k shares on-market at roughly US$1.19 per share. This was the largest purchase by an insider in the last 3 months. This was Michael's only on-market trade for the last 12 months.Executive Departure • May 30Senior VP & Chief Medical Officer has left the companyOn the 28th of May, Elizabeth Tarka's tenure as Senior VP & Chief Medical Officer ended after 1.8 years in the role. As of March 2021, Elizabeth personally held only 13.24k shares (US$17k worth at the time). Elizabeth is the only executive to leave the company over the last 12 months.Price Target Changed • Mar 16Price target increased to US$8.60Up from US$7.83, the current price target is an average from 4 analysts. New target price is 84% above last closing price of US$4.68. Stock is up 337% over the past year.分析記事 • Mar 07Is Idera Pharmaceuticals (NASDAQ:IDRA) In A Good Position To Deliver On Growth Plans?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...分析記事 • Jan 31When Will Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Become Profitable?With the business potentially at an important milestone, we thought we'd take a closer look at Idera Pharmaceuticals...Is New 90 Day High Low • Jan 20New 90-day high: US$5.40The company is up 158% from its price of US$2.09 on 21 October 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 22% over the same period.分析記事 • Dec 27Could The Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Ownership Structure Tell Us Something Useful?If you want to know who really controls Idera Pharmaceuticals, Inc. ( NASDAQ:IDRA ), then you'll have to look at the...分析記事 • Dec 27Don't Ignore The Fact That This Insider Just Sold Some Shares In Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)We'd be surprised if Idera Pharmaceuticals, Inc. ( NASDAQ:IDRA ) shareholders haven't noticed that the President...Recent Insider Transactions • Dec 26President recently sold US$161k worth of stockOn the 22nd of December, Vincent Milano sold around 37k shares on-market at roughly US$4.32 per share. This was the largest sale by an insider in the last 3 months. This was Vincent's only on-market trade for the last 12 months.Recent Insider Transactions Derivative • Dec 26President notifies of intention to sell stockVincent Milano intends to sell roughly 37.17k shares in the next 90 days after lodging an Intent To Sell Form on the 22nd of December. If the sale is conducted around the recent share price of US$4.41, it would amount to US$164k. For the year to December 2019, Vincent's total compensation was 45% salary and 55% non-salary (Indicating these sales could comprise a meaningful part of their income for the year). Since March 2020, Vincent has owned 61.25k shares directly. This was the only transaction from an insider over the last 12 months.分析記事 • Nov 25We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, Idera Pharmaceuticals...Is New 90 Day High Low • Nov 19New 90-day high: US$3.33The company is up 84% from its price of US$1.81 on 20 August 2020. The American market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Analyst Estimate Surprise Post Earnings • Nov 03Earnings beat expectationsRevenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 168%.Is New 90 Day High Low • Oct 29New 90-day high: US$2.69The company is up 35% from its price of US$1.99 on 30 July 2020. The American market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Is New 90 Day High Low • Sep 19New 90-day high: US$2.68The company is up 41% from its price of US$1.90 on 19 June 2020. The American market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.業績と収益の成長予測NasdaqCM:ACGN - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2024N/A-63N/AN/A112/31/2023N/AN/AN/AN/A13/31/20237-41-30-30N/A12/31/20225-23-24-24N/A9/30/20220-16-15-15N/A6/30/2022N/A-18-17-17N/A3/31/2022N/A-20-20-20N/A12/31/2021N/A97-25-25N/A9/30/2021N/A24-28-28N/A6/30/2021N/A9-31-31N/A3/31/2021N/A-8-33-33N/A12/31/2020N/A-113-34-34N/A9/30/2020N/A-87-37-37N/A6/30/2020N/A-78-40-40N/A3/31/20201-65-42-42N/A12/31/20191-85-45-44N/A9/30/20192-45-46-46N/A6/30/20192-46-47-47N/A3/31/20190-51-51-51N/A12/31/20181-60-52-52N/A9/30/20181-63-52-52N/A6/30/20181-66-52-52N/A3/31/20181-71-53-52N/A12/31/20171-66-55-55N/A9/30/201716-50-39-39N/A6/30/201716-49-38-38N/A3/31/201716-41-33-33N/A12/31/201616-38N/A-28N/A9/30/20161-51N/A-42N/A6/30/20161-50N/A-43N/A3/31/20161-49N/A-43N/A12/31/20150-49N/A-43N/A9/30/20150-49N/A-44N/A6/30/20150-47N/A-40N/A3/31/20150-42N/A-36N/A12/31/20140-39N/A-31N/A9/30/20140-34N/A-26N/A6/30/20140-29N/A-23N/A3/31/20140-26N/A-21N/A12/31/20130-21N/A-17N/A9/30/20130-21N/A-17N/A6/30/20130-21N/A-17N/A3/31/20130-19N/A-18N/A12/31/20120-22N/A-20N/A9/30/20120-26N/A-19N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: ACGNの予測収益成長が 貯蓄率 ( 2.2% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: ACGNの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: ACGNの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: ACGN来年は収益がないと予測されています。高い収益成長: ACGN来年は収益がないと予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: ACGNの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/08/23 12:54終値2023/08/21 00:00収益2023/03/31年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Aceragen, Inc. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。8 アナリスト機関Michael UlzBairdMichael KingCitizens JMP Securities, LLCMatthew BannonJ.P. Morgan5 その他のアナリストを表示
Price Target Changed • Aug 15Price target decreased by 88% to US$17.00Down from US$142, the current price target is provided by 1 analyst. New target price is 3,909% above last closing price of US$0.42. Stock is down 94% over the past year. The company is forecast to post a net loss per share of US$2.18 next year compared to a net loss per share of US$7.18 last year.
Price Target Changed • Mar 16Price target increased to US$8.60Up from US$7.83, the current price target is an average from 4 analysts. New target price is 84% above last closing price of US$4.68. Stock is up 337% over the past year.
分析記事 • Jan 31When Will Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Become Profitable?With the business potentially at an important milestone, we thought we'd take a closer look at Idera Pharmaceuticals...
Price Target Changed • Aug 15Price target decreased by 88% to US$17.00Down from US$142, the current price target is provided by 1 analyst. New target price is 3,909% above last closing price of US$0.42. Stock is down 94% over the past year. The company is forecast to post a net loss per share of US$2.18 next year compared to a net loss per share of US$7.18 last year.
お知らせ • May 31Aceragen Receives Nasdaq Notice Regarding Delayed Form 10-Q FilingAceragen, Inc. announced that on May 24, 2023, the Company received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company had not yet filed its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023 (the “Form 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic financial reports with the Securities and Exchange Commission. The Nasdaq notice has no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Global Market. The Company has until July 24, 2023 to submit to Nasdaq a plan to regain compliance. If Nasdaq accepts the Company’s plan, then Nasdaq may grant the Company up to 180 calendar days from the Form 10-Q’s original due date, or November 20, 2023, to regain compliance. If the Company is unable to make such filings by July 24, 2023, the Company intends to submit to Nasdaq a plan to regain compliance.
お知らせ • May 16Aceragen, Inc. announced delayed 10-Q filingOn 05/15/2023, Aceragen, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 06Aceragen, Inc. Announces John Kirby No Longer Serves as Chief Financial OfficerAceragen, Inc. announced that effective as of the Effective Date, John Kirby no longer serves as the Company’s Chief Financial Officer or is employed by the Company. Mr. Kirby is entitled to certain payments and post-termination benefits as set forth in his employment continuation and retention bonus letter agreement and his Severance and Change of Control Agreement with the Company, each as described on pages 80, 88 and 89 of the 2022 Form 10-K.
お知らせ • Feb 07Aceragen, Inc. Announces Recommendation of Data Monitoring Committee in Terra StudyAceragen, Inc. announced the recommendation of its independent Data Monitoring Committee (DMC) in regard to the on-going TERRA Phase 2 study of ACG-701 in patients with melioidosis. The DMC is responsible for providing oversight of safety and efficacy for this study and has recommended the TERRA study continue without modification. The DMC review was a planned meeting held in order to monitor the safety of the seriously ill subjects participating in the TERRA study. Aceragen has executed an ~$50 million development partnership with the Department of Defense’s Defense Threat Reduction Agency (“DTRA”) to investigate ACG-701 as a potential medical countermeasure for melioidosis, a life-threatening infection caused by the B. pseudomallei pathogen. This program is centered around a Phase 2 trial, the TERRA study (NCT05105035), which is a randomized double-blind, placebo-controlled trial conducted in hospitalized melioidosis patients. TERRA was initiated in May 2022 and continues to actively enroll patients with a data read-out expected in the fourth quarter of 2023.
お知らせ • Feb 04Aceragen, Inc. Announces Bryant D. Lim to Leave as Senior Vice President, Chief Business Officer and General Counsel of the Company, Effective February 17, 2023Aceragen, Inc. announced that on February 3, 2023, Bryant D. Lim will be leaving his role as Senior Vice President, Chief Business Officer and General Counsel of the Company, effective February 17, 2023, to pursue another opportunity.
Seeking Alpha • Sep 28Idera Pharmaceuticals completes acquisition of AceragenIdera Pharmaceuticals (NASDAQ:IDRA) has completed the acquisition of privately-held biotechnology company Aceragen in a stock-for-stock transaction. The acquisition, not subject to the approval of Idera stockholders, was unanimously approved by the board of both the companies. The combined cash of the two companies is expected help in funding the advancement of Aceragen's pipeline through 2023. Idera's former CEO, Vincent Milano, has been named board chair. Aceragen's former CEO, John Taylor, succeeds Milano. Additionally, Aceragen's former chief medical officer, Carl Kraus, will serve in that role for Idera. Also, Aceragen's former COO, Daniel Salain, will serve in that role for Idera. And, Andy Jordan, Aceragen's former CFO has been appointed chief strategy officer for Idera. IDRA shares were trading +19.85% post-market. Source: Press Release
分析記事 • Aug 24We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn RateJust because a business does not make any money, does not mean that the stock will go down. For example, although...
Board Change • Jun 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 2 highly experienced directors. Independent Chairman Mike Dougherty was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
分析記事 • May 11We Think Idera Pharmaceuticals (NASDAQ:IDRA) Needs To Drive Business Growth CarefullyJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Board Change • May 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 2 highly experienced directors. Independent Chairman Mike Dougherty was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Director Overboarding • Aug 03Director Vincent Milano has joined 3rd company boardPresident, CEO & Director Vincent Milano has been appointed to the board of BioCryst Pharmaceuticals, Inc. (NasdaqGS:BCRX). Milano now sits on a total of 3 company boards. With 3 board positions including the role of CEO at Idera Pharmaceuticals, Inc. (NasdaqCM:IDRA), the director is at risk of having too many board obligations according to the Simply Wall St Risk Model.
Director Overboarding • Aug 03Director Vincent Milano has joined 3rd company boardPresident, CEO & Director Vincent Milano has been appointed to the board of BioCryst Pharmaceuticals, Inc. (NasdaqGS:BCRX). Milano now sits on a total of 3 company boards. With 3 board positions including the role of CEO at Idera Pharmaceuticals, Inc. (NasdaqCM:IDRA), the director is at risk of having too many board obligations according to the Simply Wall St Risk Model.
Director Overboarding • Aug 03Director Vincent Milano has joined 3rd company boardPresident, CEO & Director Vincent Milano has been appointed to the board of BioCryst Pharmaceuticals, Inc. (NasdaqGS:BCRX). Milano now sits on a total of 3 company boards. With 3 board positions including the role of CEO at Idera Pharmaceuticals, Inc. (NasdaqCM:IDRA), the director is at risk of having too many board obligations according to the Simply Wall St Risk Model.
Recent Insider Transactions • Jun 22Senior VP & COO recently bought US$60k worth of stockOn the 18th of June, Daniel Soland bought around 50k shares on-market at roughly US$1.19 per share. In the last 3 months, there was an even bigger purchase from another insider worth US$101k. Daniel has been a buyer over the last 12 months, purchasing a net total of US$98k worth in shares.
Recent Insider Transactions • Jun 04Independent Chairman recently bought US$101k worth of stockOn the 1st of June, Michael Dougherty bought around 85k shares on-market at roughly US$1.19 per share. This was the largest purchase by an insider in the last 3 months. This was Michael's only on-market trade for the last 12 months.
Executive Departure • May 30Senior VP & Chief Medical Officer has left the companyOn the 28th of May, Elizabeth Tarka's tenure as Senior VP & Chief Medical Officer ended after 1.8 years in the role. As of March 2021, Elizabeth personally held only 13.24k shares (US$17k worth at the time). Elizabeth is the only executive to leave the company over the last 12 months.
Price Target Changed • Mar 16Price target increased to US$8.60Up from US$7.83, the current price target is an average from 4 analysts. New target price is 84% above last closing price of US$4.68. Stock is up 337% over the past year.
分析記事 • Mar 07Is Idera Pharmaceuticals (NASDAQ:IDRA) In A Good Position To Deliver On Growth Plans?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
分析記事 • Jan 31When Will Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Become Profitable?With the business potentially at an important milestone, we thought we'd take a closer look at Idera Pharmaceuticals...
Is New 90 Day High Low • Jan 20New 90-day high: US$5.40The company is up 158% from its price of US$2.09 on 21 October 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 22% over the same period.
分析記事 • Dec 27Could The Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Ownership Structure Tell Us Something Useful?If you want to know who really controls Idera Pharmaceuticals, Inc. ( NASDAQ:IDRA ), then you'll have to look at the...
分析記事 • Dec 27Don't Ignore The Fact That This Insider Just Sold Some Shares In Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)We'd be surprised if Idera Pharmaceuticals, Inc. ( NASDAQ:IDRA ) shareholders haven't noticed that the President...
Recent Insider Transactions • Dec 26President recently sold US$161k worth of stockOn the 22nd of December, Vincent Milano sold around 37k shares on-market at roughly US$4.32 per share. This was the largest sale by an insider in the last 3 months. This was Vincent's only on-market trade for the last 12 months.
Recent Insider Transactions Derivative • Dec 26President notifies of intention to sell stockVincent Milano intends to sell roughly 37.17k shares in the next 90 days after lodging an Intent To Sell Form on the 22nd of December. If the sale is conducted around the recent share price of US$4.41, it would amount to US$164k. For the year to December 2019, Vincent's total compensation was 45% salary and 55% non-salary (Indicating these sales could comprise a meaningful part of their income for the year). Since March 2020, Vincent has owned 61.25k shares directly. This was the only transaction from an insider over the last 12 months.
分析記事 • Nov 25We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, Idera Pharmaceuticals...
Is New 90 Day High Low • Nov 19New 90-day high: US$3.33The company is up 84% from its price of US$1.81 on 20 August 2020. The American market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Analyst Estimate Surprise Post Earnings • Nov 03Earnings beat expectationsRevenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 168%.
Is New 90 Day High Low • Oct 29New 90-day high: US$2.69The company is up 35% from its price of US$1.99 on 30 July 2020. The American market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Is New 90 Day High Low • Sep 19New 90-day high: US$2.68The company is up 41% from its price of US$1.90 on 19 June 2020. The American market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.